19 July 2019 - BEAM Alliance

BEAM Alliance: Time to give your feedback on how to characterize antimicrobial activity!

The BEAM Alliance proposed a six-way approach to characterize ATM activity, with the aim of opening new doors in the…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

BEAM News
Member News
Events

Latest news of BEAM Alliance

19 July 2019 - BEAM Alliance

BEAM Alliance: Time to give your feedback on how to characterize antimicrobial activity!

The BEAM Alliance proposed a six-way approach to characterize ATM activity, with the aim of opening new doors in the…

06 June 2019 - BEAM Alliance

Emergency on planet AMR: a vital pipeline to protect

The sooner we come up with practical solutions, the more SMEs (and currently developed products) we can save from vanishing.…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

24 September 2018 - BEAM Alliance

Antibiorésistance : BEAM Alliance tire la sonnette d’alarme

Priorités : Alerter les pouvoirs publics sur le besoin médical et l’urgence associés à la pénurie de nouveaux traitements contre…

07 June 2018 - BEAM Alliance

BEAM writes to Representatives of the US congress to support The Pandemic and All Hazards Preparedeness Act (PAHPA) currently discussed at the House of Representatives.

BEAM writes to Representatives of the US congress to support The Pandemic and All Hazards Preparedeness Act (PAHPA) currently discussed…

page 1/3

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

09 September 2019 - Nabriva Therapeutics GmbH

Nabriva’s XENLETA™ (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S.

XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics…

06 September 2019 - Nabriva Therapeutics GmbH

Nabriva Therapeutics Earns $5 Million Milestone Payment under its License Agreement with Sinovant Sciences

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.…

20 August 2019 - Nabriva Therapeutics GmbH

Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta™ (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP)

“Today’s approval of XENLETA is a significant breakthrough in the collective fight against the growing threat of antimicrobial resistance and…

22 July 2019 - AMR Centre Ltd

The AMR Centre set for partnership with Shionogi for new superbug therapy

Dr Peter Jackson, executive director of the AMRC, said: “COT-143 is an advanced program that has produced very promising data…

17 July 2019 - Polyphor Ltd

Polyphor closes the Phase III PRISM studies of murepavadin intravenous formulation and evaluates further product improvement options

“We would like to thank the patients, the investigators and all the scientists involved for their contribution to the development…

16 July 2019 - Pherecydes Pharma

Pherecydes Pharma and BIOASTER join forces to explore the use of phage therapy to treat complicated urinary tract infections

“This project will be an important step forward for phage therapy and a new hope for patients,” commented Guy-Charles Fanneau…

page 1/14

Events

10 September 2019

REVIVE webinar: Models for antimicrobial R&D: Advanced and complex in vivo models for infectious disease research

In this webinar, Peter Warn will review the experimental design and conduct of advanced or complex animal models for antimicrobial…

06 September 2019

CeBIL Annual Symposium 2019: Legal Innovation to Support the Development of Antimicrobial Drugs

This symposium will explore the complex interactions between law and antimicrobial research and development. Advancing our understanding of this ecosystem…

03 September 2019

ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

Antimicrobial drug resistance (AMR) is an urgent global health problem. New antimicrobial drug development is increasingly viewed as a priority…

20 August 2019

REVIVE webinar: Models for antimicrobial R&D: Computational modelling for population PK and PKPD

In this webinar, Lena Friberg and Elisabet Nielsen (Department of Pharmaceutical Biosciences, Uppsala University, Sweden), will discuss: - Population PK…

16 July 2019

OBN BioTuesday: What’s New in Antimicrobial Resistance – is there light at the end of the tunnel?

The development of resistance to antimicrobials threatens to reverse the changes in public health that have occurred over the last…

09 July 2019

REVIVE webinar: Infection models for antimicrobial R&D: Intracellular models

In this webinar, Françoise van Bambeke, Research Director Cellular and Molecular Pharmacology, Louvain Drug Research Institute, Catholic University of Louvain…

11 June 2019

REVIVE webinar: Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research

In this webinar, William J. Weiss, Director, PreClinical Services, University of North Texas System College of Pharmacy, will introduce experimental…

05 June 2019

Advancing Data Technologies to corner Antimicrobial Resistance

Antimicrobial resistance (AMR) already now is the largest global threat to Health and Food Safety (source: WHO). Without the focused…

03 June 2019

BIO International Convention

The key benefits of attending the 2019 BIO International Convention are access to global biotech and pharma leaders via BIO…

page 2/4